• Login
  • Register
Nairametrics
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Economy
    • Nairalytics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Business News
    • Budget
    • Public Debt
    • Funds Management
    • Tax
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
    • Research Analysis
  • Recapitalization
    • Access Holdings Offer
    • Fidelity Bank Offer
    • GTCO Offer
    • Zenith Bank Offer
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Economy
    • Nairalytics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Business News
    • Budget
    • Public Debt
    • Funds Management
    • Tax
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
    • Research Analysis
  • Recapitalization
    • Access Holdings Offer
    • Fidelity Bank Offer
    • GTCO Offer
    • Zenith Bank Offer
Nairametrics
No Result
View All Result
Home Companies Corporate Updates

Emzor signs agreement with Mangalam for local manufacture of active pharmaceutical ingredients, APIs

NM Partners by NM Partners
August 28, 2021
in Corporate Updates
Emzor signs agreement with Mangalam for local manufacture of active pharmaceutical ingredients, APIs
Share on FacebookShare on TwitterShare on Linkedin

Emzor announces API Manufacturing Technology Transfer and Licensing Agreement with India’s Mangalam Drugs & Organics Limited, to locally manufacture in Nigeria and distribute Active Pharmaceutical Ingredients (APIs) for the treatment and prevention of malaria.

The arrangement includes an API technology transfer and licensing agreement which establishes a co-development basis for manufacturing 4 APIs for the treatment of malaria which continues to be a leading cause of death on the African continent.

This will lead to the development of a world class API manufacturing facility in full compliance with international standards and the first of its kind in the sub-Saharan African region. The agreement reaffirms Emzor’s long-standing commitment to strengthening the pharma sector in Africa. The signed technology transfer and licensing agreement with Mangalam, a leading Indian chemical manufacturing company will provide in-house developed technology for manufacturing antimalarial Active Pharmaceutical Ingredients (APIs). As part of the agreement, Mangalam will also provide consultation and relevant designs for setting up a world class API manufacturing facility compliant with WHO standards. The initial focus will be on the development of 4 APIs: artemether, lumefantrine, sulfadoxine and pyrimethamine.

RelatedStories

FG looking to patronize local manufacturers for health sector procurement – Health Ministry

FG looking to patronize local manufacturers for health sector procurement – Health Ministry

June 26, 2021

The selected APIs provide chemo-preventive combination therapies for malaria in pregnant women as well as treatment for adults and children. Malaria remains the leading cause of death in Nigeria. According to the 2020 World Malaria Report, Nigeria had the highest number of global malaria cases (27 % of global malaria cases) in 2019 and accounted for the highest number of deaths (23 % of global malaria deaths). Emzor is a pioneer in the Nigerian malaria space and was the first Nigerian indigenous pharmaceutical company to develop and manufacture artemether/lumefantrine, under the brand name Lokmal, launched in 2009.

Artemether/Lumefantrine is a WHO-recommended Artemisinin Combination Therapy (ACT). Maldox is Emzor’s brand name for its sulfadoxine and pyrimethamine (S/P) combination antimalarial. The use of (S/P) in IPTp (intermittent preventive treatment of malaria in pregnancy) has been a key contributor to the reduction of maternal (and child) mortality and the negative health impact of malaria on survivors. Emzor is at an advanced stage in the process of submitting a dossier to WHO-prequalification for Maldox, a project supported by Medicines for Malaria Venture (MMV) with funding from UNITAID.

Emzor currently manufactures 19 SKUs of anti-malarial and this continued focus and strategy builds on Emzor’s strength in maternal and child health. It cements the firm’s commitment to impacting the therapeutic areas that have the greatest impact on this vulnerable segment of society. The agreement represents an excellent opportunity for local manufacturing and backward integration which supports the firm’s vision to reduce the cost of drugs and the supply chain issues often affecting the distribution and global response, particularly in times of crises as has been recently experienced with the COVID-19 pandemic. Additionally, this agreement with Mangalam is an apt response to the complete dependency on external firms for APIs to sustain the regional pharmaceutical industry.

The successful launch of such an undertaking will require other collaborations, so with that we are also proud to partner with API For Africa (APIFA). APIFA is a not-for-profit organization facilitating the local production of APIs in sub-Saharan Africa. They work with a multitude of critical stakeholders (manufacturers, investors, Development Finance Institutions (DFIs), donors, governments), to address the major challenge of the lack of significant API manufacturing capacity in sub-Saharan Africa. They will be invaluable as we also seek to export some of the API production volume to other African pharmaceutical manufacturers of finished products. Dr Stella Okoli, Emzor’s founder and Managing Director said “We give God all the glory and praise Him for this great privilege and opportunity to serve Nigerians, Africans and humanity. This deal is exciting for us as it provides Emzor an opportunity to become a leader in the global fight against malaria and lends to our tireless commitment to bring affordable drugs for all. The agreement is not just a victory for Emzor; by being able to manufacture at this level locally, in time we will drive the expansion of our national chemical industries, provide opportunities to utilize the petrochemical industry for making key starting intermediates, create local jobs and reduce the cost of drugs to those that need it the most. However, most importantly we begin the journey to self-reliance and sustainability of the pharma sector in Africa and enhance our ability to respond in times of global emergencies.”

About Emzor

Emzor is a privately owned indigenous pharmaceutical company founded in 1984 by Dr Stella Okoli. The Company has grown into a legacy pharmaceutical company with 4 modern factories that manufacture over 140 world-class pharmaceutical products, such as analgesics (the widely used Emzor Paracetamol), vitamins, haematinics, anti-malarial, anti-tussive, antibiotics, antihelminthic, anti-histamine, antacid, and cardio-protective drugs. Emzor has a network of over 120 distributors covering public and private institutions across West Africa.

About Mangalam Drugs & Organic Limited

Mangalam commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and Intermediates at VAPI – Gujarat in 1977. It has a multi-product manufacturing facility on two locations, and an in-house Research & Development laboratory recognized by the Department of Scientific & Industrial Research, Delhi Govt. of India (DSIR). Over the last three decades, Mangalam has acquired worldwide reputation as a single stop destination for frontline Antimalaria APIs including Pyrimethamine, Sulfadoxine, Artemether, and Lumefantrine. It is a WHOGENEVA GMP Certificated facility and EDQM approved for its API manufacturing plant. It also has an agreement in place with the prestigious Clinton Health Access Initiatives (CHAI) under its Fight Malaria Program for supply of anti-malaria APIs worldwide.

About Medicines for Malaria Venture (MMV)

MMV is a leading product development partnership (PDP) in the field of antimalarial drug research and development. Its mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs.

About API for Africa (APIFA)

APIFA is a not for profit platform that works in partnership with local pharmaceutical manufacturers in sub-Saharan Africa to develop manufacturing capacity for Active Pharmaceutical Ingredients (APIs) and other related services. APIFA believes in the development of a thriving African pharmaceutical manufacturing industry and the employment, skill-building and positive spill over effects that would come with that, but more importantly, a resilient and stable health system and future economic growth.

Tags: EmzorMangalam Drugs & Organic Limited
NM Partners

NM Partners

"NM Partners" encompasses a diverse range of articles and content published on behalf of various organizations, including corporate entities, government and non-governmental institutions, academic bodies, and key stakeholders in the economic sphere. This content spectrum covers press releases, formal announcements, specialized content, product promotions, and a variety of corporate communications tailored to engage our readership. Notably, a portion of these articles are sponsored content. At Nairametrics, while we provide a platform for these diverse voices, it is important to clarify that our relationship with the content under "NM Partners" does not imply endorsement or affiliation. The responsibility for the content accuracy and viewpoints expressed rests solely with the respective contributors. Nairametrics maintains a firm commitment to editorial independence and integrity. Consequently, we do not assume responsibility for any of the content published under "NM Partners." For any inquiries, comments, or feedback regarding the content featured in this section, we encourage open communication and can be reached at info@nairametrics.com. Additionally, we invite our readers and contributors to familiarize themselves with our Paid Post Guidelines, which outline the standards and processes governing paid content on our platform.

Related Posts

FG looking to patronize local manufacturers for health sector procurement – Health Ministry
Business News

FG looking to patronize local manufacturers for health sector procurement – Health Ministry

June 26, 2021
Next Post
Are NFTs the new way of making money?

Are NFTs the new way of making money?

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

nlng
Zenth Bank
Emple
first bank
Zenth Bank








DUNS

Recent News

  • IMTO inflows surge by 45% to $4.76 billion in 2024 amid CBN reforms 
  • What does liquidity mean in crypto? 
  • How to choose the best forex broker: Key factors to consider

Follow us on social media:

Recent News

CBN, forex

IMTO inflows surge by 45% to $4.76 billion in 2024 amid CBN reforms 

May 23, 2025
What does liquidity mean in crypto? 

What does liquidity mean in crypto? 

May 23, 2025
  • iOS App
  • Android App
  • Contact Us
  • Home
  • Markets
  • Sectors
  • Economy
  • Business News
  • Financial Literacy
  • Disclaimer
  • Ads Disclaimer
  • Copyright Infringement

© 2025 Nairametrics

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Social Media Auto Publish Powered By : XYZScripts.com
No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Economy
    • Nairalytics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Business News
    • Budget
    • Public Debt
    • Funds Management
    • Tax
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
    • Research Analysis
  • Recapitalization
    • Access Holdings Offer
    • Fidelity Bank Offer
    • GTCO Offer
    • Zenith Bank Offer
  • Login
  • Sign Up

© 2025 Nairametrics